Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

1.1K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.1K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

225
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
225
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

482
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
482
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

229
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
229
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

227
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
227
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

234
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
234

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LATAM-AKID registry: an international multicentre, observational study of acute kidney injury requiring dialysis in Latin America.

BMJ open·2026
Same author

The impact of social determinants of health on acute kidney injury.

Nature reviews. Nephrology·2026
Same author

Impact of CKD on Life Participation in Latin America.

Kidney international reports·2026
Same author

Effect of Intravenous Iron Dextran on Kidney Outcomes in Acute Kidney Injury with Iron Deficiency: A Randomized Trial.

Kidney360·2026
Same author

Empowering the next generation for kidney health advancement worldwide: the Young Nephrologists Committee of the International Society of Nephrology.

Kidney international·2026
Same author

Climate change and AKI: heat, hazards and health-system readiness.

Nature reviews. Nephrology·2026

Related Experiment Video

Updated: Feb 7, 2026

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats
05:09

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats

Published on: February 8, 2022

3.0K

Dose in continuous renal replacement therapy.

Rolando Claure-Del Granado1

  • 1Hospital Obrero #2 - C.N.S., Universidad Mayor de San Simon, School of Medicine, Cochabamba, Bolivia.

Gaceta Medica De Mexico
|August 4, 2018
PubMed
Summary

Continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) requires dynamic dosing. While recent trials suggest a 20-25 mL/kg/h effluent dose, ongoing assessment and monitoring are crucial for optimal patient outcomes.

Keywords:
Acute kidney injuryContinuous renal replacement therapyDosis administradaDosis prescritaLesión renal agudaPrescribed dose. Delivered doseTerapia de reemplazo renal continuoUrea

More Related Videos

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.3K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.2K

Related Experiment Videos

Last Updated: Feb 7, 2026

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats
05:09

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats

Published on: February 8, 2022

3.0K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.3K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.2K

Area of Science:

  • Nephrology
  • Critical Care Medicine

Background:

  • Continuous renal replacement therapy (CRRT) is vital for critically ill patients with acute kidney injury (AKI).
  • Recent clinical trials inform current practice guidelines for CRRT dosing.

Purpose of the Study:

  • To emphasize the importance of individualized CRRT dose prescription.
  • To highlight the need for dynamic dose adjustment based on patient-specific factors.
  • To underscore the necessity of monitoring delivered CRRT dose.

Main Methods:

  • Analysis of recent clinical trials on CRRT intensity.
  • Review of current practice guidelines for CRRT dosing.
  • Discussion of proposed quality measures for monitoring delivered CRRT dose.

Main Results:

  • Recent trials indicate no significant outcome differences between high- and low-intensity CRRT (20-25 mL/kg/h effluent).
  • Evidence suggests CRRT dose requires continuous assessment and modification based on patient needs.
  • Proposed quality measures for monitoring delivered CRRT dose require further validation.

Conclusions:

  • CRRT dose prescription must be dynamic, precise, and guided by evidence-based quality measures.
  • Routine monitoring of delivered CRRT dose is essential to ensure prescribed targets are met.
  • Validated quality measures are needed for effective implementation in clinical practice.